CD38 and Miyoshi myopathy: Several T-BsAbs, as well as bispecific T-cell engagers (BiTEs) targeting BCMA, GPRC5D, CD38 and FcRH5 have demonstrated impressive clinical activity in MM patients (Fig. 4).